FDA sets May 2027 decision date as pivotal trial finalizes
- The FDA accepted the AMT-130 BLA with priority review, setting a May 1, 2027 decision date.
- The required confirmatory trial design is finalized, evaluating a 36-month functional endpoint.
- Cash reserves stood at $768.4 million at the end of Q3 2026, extending the operational runway into 2030.
- AMT-260 showed 79 to 100 percent seizure reductions in half of low-dose patients.
- The company expects an FDA Advisory Committee meeting for AMT-130, adding binary regulatory risk.
One asset, two regulators, renewed hope
In late 2026, the FDA accepted uniQure's Biologics License Application for accelerated approval of AMT-130. The agency granted priority review and set a target action date of May 1, 2027. The U.K. regulator also validated a corresponding marketing application.
A massive cash balance of $768.4 million extends the runway into 2030, giving the company years of flexibility to fund its operations. The company also finalized the design for its required confirmatory trial, aiming to enroll approximately 200 patients.
The bull case is clear. The U.S. accelerated approval pathway has a concrete decision date, and the company has the cash to follow it. Furthermore, the pipeline is showing early life, with the AMT-260 epilepsy program demonstrating meaningful seizure reductions in its lowest dose cohort.
The bear case centers on the regulatory finish line. The FDA expects the required standard-of-care confirmatory trial to be well underway by the time of any accelerated approval. The agency also set a high bar by requiring Total Functional Capacity at 36 months as the confirmatory endpoint. An expected Advisory Committee meeting adds significant binary risk before the May 2027 decision.
Royalties fund a trial story
uniQure develops one-time gene therapies for serious rare diseases. These treatments try to fix or change disease biology with a single administration, rather than requiring chronic dosing.
The only approved product tied to uniQure is HEMGENIX for Hemophilia B. CSL Behring commercializes it, and uniQure receives royalties and milestone payments. License revenue makes up the vast majority of the revenue base today.
The company previously subcontracted its manufacturing of HEMGENIX to Genezen. In April 2026, uniQure agreed to terminate this commercial supply agreement, ending its supply obligation once specified batches are delivered. The company relies on outsourced manufacturing for its clinical-stage pipeline.
The core value driver is the clinical and regulatory success of its pipeline. The business relies on a massive cash reserve to fund costly trials until its candidates can be commercialized or licensed.
What uniQure is betting on
AMT-130
The lead program for Huntington's disease. The FDA accepted its BLA for priority review with a May 1, 2027 target action date.
HEMGENIX
An approved gene therapy for Hemophilia B sold by CSL Behring. It provides royalty revenue but is not the primary driver of the stock.
AMT-260
A clinical candidate for refractory mesial temporal lobe epilepsy. Early data showed meaningful seizure reductions for a subset of low-dose patients.
AMT-191
A clinical candidate for Fabry disease. Dosing in mid- and high-dose cohorts remains paused pending evaluation of dose-limiting toxicities.
Revenue is one stream today
For Q3 2026, uniQure reported revenue primarily from licenses. The company operates as a single business segment focused on gene therapy development.
What could break the story
Confirmatory trial requirements
High impact · High oddsThe FDA accepted the BLA submission, but it requires a 200-patient standard-of-care confirmatory trial to be well underway before potential approval. The FDA wants Total Functional Capacity at 36 months as the primary endpoint, which is a very high bar.
Advisory Committee risk
High impact · Medium oddsManagement expects an FDA Advisory Committee meeting for the AMT-130 application. This public review introduces severe binary risk, as the panel will heavily scrutinize the intermediate endpoints and safety profile.
Pipeline safety setbacks
Medium impact · Medium oddsDosing in the AMT-191 trial for Fabry disease is paused due to dose-limiting toxicities. Early-stage development risk remains high across the broader portfolio.
BLA review timelines
High impact · Medium oddsThe FDA accepted the BLA with a May 2027 action date, but could still issue a complete response letter. A rejection would severely damage the stock.
In one breath
What is the status of AMT-130?
The FDA accepted a U.S. Biologics License Application for accelerated approval, setting a target decision date of May 1, 2027. The company also has an application under review in the U.K.
How is uniQure funded?
The company reported $768.4 million in cash and investments at the end of Q3 2026, extending its runway into 2030. The company also earns royalties on HEMGENIX.
What happened to the manufacturing business?
uniQure terminated its commercial supply agreement with Genezen in April 2026. It is moving away from supplying HEMGENIX after final batches are delivered.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near uniQure N.V. in Finn's Biotechnology industry ranking.

